AKAnn Hau-Yu Kwan

Ann Hau-Yu Kwan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ann Hau-Yu Kwan has a total of 331 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial modulation enhances the effects of radiation on prostate cancer cells: a targeted mass spectrometry metabolomics study

    by Biqi Chen, Linda J. Rogers, Kelvin Liu, Sida Chen, Rexhmir Deda, Michael P. Gotsbacher, Jean Yang, David R. McKenzie, Natalka Suchowerska, Ann H. Kwan

    Traditional radiotherapy practice prescribes a uniform radiation dose to the target volume, based on the assumption that the most effective outcome is achieved when all cancer cells receive the pre...

  • Open Access

    Porphyrin pathways as targets for combating antimicrobial resistance: virulence and therapeutic opportunities

    by Alysha Pyne, Jameel M. Abduljalil, Ann H. Kwan

    Porphyrins are versatile biomolecules central to the synthesis of many essential molecules across all domains of life. Their ability to absorb light, accept electrons and facilitate redox reactions underpins diverse biological roles. Importantly, porphyrin properties can be easily tailored through substitutions of side chains and chelated metals. This adaptability has enabled porphyrins to play critical roles in bacterial environmental adaptations, most notably in enhancing competitive advantage and virulence. The association between porphyrin adaptations and virulence in pathogenic bacteria presents a unique opportunity for the development of next-generation antibacterial strategies and therapeutics. By focusing on virulence and virulence-related systems, these innovative strategies aim to address antimicrobial resistance by reducing the selective pressures that drive its emergence, promote evolutionary pathways that favor non-pathogenic adaptations and help to restore the balance of commensal microbiota. This review highlights the recent advances in porphyrin and porphyrin-related antibiotic developments, with emphasis on approaches targeting virulence versus bacterial survival. We further discuss emerging virulence-targeted therapeutics, including artificial intelligence and machine learning for novel target and lead discovery.


  • Open Access

    Antibacterial Drug Discovery: Deep Learning Successes and Challenges through the Structural Biology Lens

    by Jameel M. Abduljalil, Sandro F. Ataide, Ann H. Kwan

    The continuous rise of multidrug-resistant pathogens necessitates an urgent need for new antibiotics, yet innovation in antibiotic discovery has largely stalled since the 1980s. In traditional drug development, around 90% of candidate molecules fail at the preclinical stage or phase I of trials due to toxicity or lack of efficacy. Effective antibiotic discovery must overcome a set of microbiological challenges: selective bacterial targeting, penetration of complex cell envelopes, and evasion of diverse resistance mechanisms. Recent advances in deep learning (DL) offer promising opportunities to address these challenges. DL can help identify and characterize new bacterial targets, predict accurate 3-dimensional structures, assess druggability, and discover lead molecules with antibiotic potential. Generative models further enable the de novo design of candidates with optimized pharmacokinetics and safety profiles, potentially resolving long-standing toxicity issues. These technologies streamline labor-intensive screening and boost efficiency in the drug discovery pipeline. However, DL methods need to be applied judiciously. Their effectiveness depends on appropriate model selection, high-quality training data, and careful interpretation of predictions particularly when predicting properties for novel microbial targets. This review provides a timely and critical analysis of DL applications in antibacterial hit discovery through the lens of structural biology, offering structural biologists a road map for integrating these tools into antibiotic discovery workflows to help combat antimicrobial resistance.


  • Top Cited Papers
    Open Access

    Colouring dysbiosis: FetB-dependent Mn-PPIX produced by Porphyromonas gingivalis shapes the oral microbiota

    by Yupaporn Phonok, Alysha Pyne, Siyuan Liu, Sandro F. Ataide, Haijing Gu, Xiaoyan Zhou, Jinlong Gao, Ann H. Kwan

    Polymicrobial diseases, such as periodontitis, are shaped by microbial interactions and nutrient‑responsive metabolic adaptations. Here, we identify novel porphyrin pigments produced by Porphyromonas gingivalis in response to haemoglobin concentrations resembling those found in the gingival sulcus and periodontal pocket. Under these conditions, P. gingivalis develops a distinctive pink, highly fluorescent phenotype. Spectroscopic and mass‑spectrometric analyses revealed the accumulation of protoporphyrin IX (PPIX), manganese‑substituted PPIX (Mn‑PPIX), and haem. Deletion of the haemin‑binding protein gene fetB greatly reduced Mn‑PPIX production and fluorescence, whereas complementation restored both. Structural and biochemical characterisation demonstrated that FetB shares homology with bacterial metal chelatases and catalyses the insertion of metal ions into tetrapyrrole rings. Mn‑PPIX exhibited selective antimicrobial activity against several oral bacteria, including Streptococcus mitis, Streptococcus salivarius, Enterococcus faecalis, and oral Lactobacillus species, while other streptococci were resistant. These findings indicate that P. gingivalis modulates porphyrin metabolism in response to host‑derived haemoglobin, producing extracellular pigments with selective antimicrobial properties that may shape the oral community and promote dysbiosis. Targeting Mn‑PPIX production or limiting haemoglobin availability may offer new strategies to restore microbial balance and mitigate disease progression.


  • Open Access

    Direct effector recognition by a tandem kinase triggers non-canonical immunity in wheat

    by Caitlin Lemmer, Emmanuel N. Annan, Benjamin Schwessinger, Eric Pereira, Bayantes Dagvadorj, Di Xiao, Brande B. H. Wulff, Simon G. Krattinger, Ann Kwan, Jameel M. Abduljalil, et al.

    Summary: Tandem kinase proteins (TKPs) are an important class of disease resistance genes in cereal crops alongside nucleotide-binding (NB-ARC) leucine-rich repeat (LRR) (NLR) receptors. Here, we cloned the wheat ( Triticum aestivum ) resistance gene Lr41 , which encodes a TKP with a C-terminal fusion, and its paired effector gene AvrLr41 from the rust pathogen Puccinia triticina . AvrLr41 is unusually large and highly divergent from most fungal effectors and is directly recognized by Lr41 through its pseudokinase domain. Immune activation mediated by Lr41 require auxiliary helper proteins, including either a minimal coiled-coil (CC) helper protein or its full-length NLR ortholog. These findings reveal a non-canonical immune system in which a kinase-type receptor directly recognizes an effector and recruits either CC or NLR helpers, demonstrating that full-length NLRs are not strictly required for NLR-linked immune execution and expanding the functional repertoire of disease resistance proteins in crops.


  • Open Access

    Peptide nucleic acids can form hairpins and bind RNA-binding proteins

    by Yichen Zhong, Lorna Wilkinson-White, Esther Zhang, Biswaranjan Mohanty, Belinda B. Zhang, Madeline S. McRae, Rachel Luo, Thomas A. Allport, Anthony P. Duff, Jennifer Zhao, et al.

    RNA-binding proteins (RBPs) are a major class of proteins that interact with RNAs to change their fate or function. RBPs and the ribonucleoprotein complexes they constitute are involved in many essential cellular processes. In many cases, the molecular details of RBP:RNA interactions differ between viruses, prokaryotes and eukaryotes, making prokaryotic and viral RBPs good potential drug targets. However, targeting RBPs with small molecules has so far been met with limited success as RNA-binding sites tend to be extended, shallow and dynamic with a mixture of charged, polar and hydrophobic interactions. Here, we show that peptide nucleic acids (PNAs) with nucleic acid-like binding properties and a highly stable peptide-like backbone can be used to target some RBPs. We have designed PNAs to mimic the short RNA stem-loop sequence required for the initiation of prokaryotic signal recognition particle (SRP) assembly, a target for antibiotics development. Using a range of biophysical and biochemical assays, the designed PNAs were demonstrated to fold into a hairpin structure, bind the targeted protein and compete with the native RNA hairpin to inhibit SRP formation. To show the applicability of PNAs against other RBPs, a PNA was also shown to bind Nsp9 from SARS-CoV-2, a protein that exhibits non-sequence-specific RNA binding but preferentially binds hairpin structures. Taken together, our results support that PNAs can be a promising class of compounds for targeting RNA-binding activities in RBPs.


  • Surface-Induced Hydrophobin Assemblies with Versatile Properties and Distinct Underlying Structures

    by Rezwan Siddiquee, Victor Lo, Caitlin L. Johnston, Aston W. Buffier, Sarah R. Ball, Jonathan L. Ciofani, Yi Cheng Zeng, Mahiar Mahjoub, Wojciech Chrzanowski, Shahrzad Rezvani-Baboli, et al.

    Hydrophobins are remarkable proteins due to their ability to self-assemble into amphipathic coatings that reverse surface wettability. Here, the versatility of the Class I hydrophobins EASΔ15 and DewY in diverse nanosuspension and coating applications is demonstrated. The hydrophobins are shown to coat or emulsify a range of substrates including oil, hydrophobic drugs, and nanodiamonds and alter their solution and surface behavior. Surprisingly, while the coatings confer new properties, only a subset is found to be resistant to hot detergent treatment, a feature previously thought to be characteristic of the functional amyloid form of Class I hydrophobins. These results demonstrate that substrate surface properties can influence the molecular structures and physiochemical properties of hydrophobin and possibly other functional amyloids. Functional amyloid assembly with different substrates and conditions may be analogous to the propagation of different polymorphs of disease-associated amyloid fibrils with distinct structures, stability, and clinical phenotypes. Given that amyloid formation is not required for Class I hydrophobins to serve diverse applications, our findings open up new opportunities for their use in applications requiring a range of chemical and physical properties. In hydrophobin nanotechnological applications where high stability of assemblies is required, simultaneous structural and functional characterization should be carried out. Finally, while results in this study pertain to synthetic substrates, they raise the possibility that at least some members of the pseudo-Class I and Class III hydrophobins, reported to form assemblies with noncanonical properties, may be Class I hydrophobins adopting alternative structures in response to environmental cues.


  • An omics approach to delineating the molecular mechanisms that underlie the biological effects of physical plasma

    by Lou I. S. A. Gonzales, Jessica W. Qiao, Aston W. Buffier, Linda J. Rogers, Natalka Suchowerska, David R. McKenzie, Ann H. Kwan

    The use of physical plasma to treat cancer is an emerging field, and interest in its applications in oncology is increasing rapidly. Physical plasma can be used directly by aiming the plasma jet onto cells or tissue, or indirectly, where a plasma-treated solution is applied. A key scientific question is the mechanism by which physical plasma achieves selective killing of cancer over normal cells. Many studies have focused on specific pathways and mechanisms, such as apoptosis and oxidative stress, and the role of redox biology. However, over the past two decades, there has been a rise in omics, the systematic analysis of entire collections of molecules in a biological entity, enabling the discovery of the so-called “unknown unknowns.” For example, transcriptomics, epigenomics, proteomics, and metabolomics have helped to uncover molecular mechanisms behind the action of physical plasma, revealing critical pathways beyond those traditionally associated with cancer treatments. This review showcases a selection of omics and then summarizes the insights gained from these studies toward understanding the biological pathways and molecular mechanisms implicated in physical plasma treatment. Omics studies have revealed how reactive species generated by plasma treatment preferentially affect several critical cellular pathways in cancer cells, resulting in epigenetic, transcriptional, and post-translational changes that promote cell death. Finally, this review considers the outlook for omics in uncovering both synergies and antagonisms with other common cancer therapies, as well as in overcoming challenges in the clinical translation of physical plasma.


  • Expression and purification of the NG domain from human SRα, a key component of the Signal Recognition Particle (SRP) receptor

    by Madeline S. McRae, Brendon Wang, RobertM.G. Hyson, Rezwan Siddiquee, Anthony P. Duff, Sandro F. Ataide, Ann H. Kwan


  • Cancer stem cell characteristics and their potential as therapeutic targets

    by Jacqueline R. Lim, Josette Mouawad, Olivia K. Gorton, William A. Bubb, Ann H. Kwan

    Cancer stem cells (CSCs) are a tumour subpopulation whose capacity for self-renewal, differentiation and proliferation generates unfavourable patient outcomes, including therapeutic resistance and metastasis. Much research has focused on the generation, biomarkers and therapeutic resistance of CSCs, as well as the development of CSC-targeted therapies. Reviews to date have either addressed general CSC characteristics or focused on CSCs from a well-studied cancer. Increasingly, specific treatment plans based on identification of molecular features and biomarkers of a patient’s cancer, rather than classification according to tissue origin or bulk tumour properties, are leading to better patient outcomes. Here, we compare CSC characteristics, specifically their biomarkers and molecular features, and identify those that are common to a number of cancers. Identification of CSC markers that suggest therapeutic strategies has led to several successful in vitro and animal tests, recommending clinical trials of treatments with potentially enhanced therapeutic benefits, especially for recurring cancers.